Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-Month follow-up of a randomized, double-blinded phase 2 trial

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Laurens, Matthew B ^a   Thera, Mahamadou A ^b   Coulibaly, Drissa ^b   Ouattara, Amed ^a,b   Kone, Abdoulaye K ^b   Guindo, Ando B ^b   Traore, Karim ^b   Traore, Idrissa ^b   Kouriba, Bourema ^b   Diallo, Dapa A ^b   Diarra, Issa ^b   Daou, Modibo ^b   Dolo, Amagana ^b   Tolo, Youssouf ^b   Sissoko, Mahamadou S ^b   Niangaly, Amadou ^b   Sissoko, Mady ^b   Takala Harrison, Shannon ^a   Lyke, Kirsten E ^a   Wu, Yukun ^a   Blackwelder, William C ^a   Godeaux, Olivier ^c   Vekemans, Johan ^c   Dubois, Marie Claude ^c   Ballou, W Ripley ^c   Cohen, Joe ^c   Dube, Tina ^d   Soisson, Lorraine ^e   Diggs, Carter L ^e   House, Brent ^f   Bennett, Jason W ^f   Lanar, David E ^f   Dutta, Sheetij ^f   Heppner, D Gray ^f   Plowe, Christopher V ^a   Doumbo, Ogobara K ^b   more..

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b Université des Sciences des Techniques et des Technologies de Bamako   (Mali)

^c GSK   (Belgium)

^d EMMES CORPORATION   (United States)

^e UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELES; ANTIGENS, PROTOZOAN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MALI; PLASMODIUM FALCIPARUM;

EID: 84894187377     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079323     Document Type: Article

References (33)

1. Plowe CV, Alonso P, Hoffman SL (2009) The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 200: 1646-1649. 10.1086/646613 [doi].
2. Heppner DG, Jr., Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, et al. (2005) Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23: 2243-2250. S0264-410X(05)00202-1 [pii];10.1016/j.vaccine.2005.01.142 [doi].
3. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, et al. (2002) Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun 70: 3101-3110. (Pubitemid 34564173)
4. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364: 1411-1420. (Pubitemid 39370716)
5. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, et al. (2009) Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 200: 329-336. 10.1086/600119 [doi].
6. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521-2532. NEJMoa0807381 [pii];10.1056/NEJMoa0807381 [doi].
7. Lell B, Agnandji S, von Glasenapp I, Haertle S, Oyakhiromen S, et al. (2009) A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 4: e7611. 10.1371/journal.pone.0007611 [doi].
8. Owusu-Agyei S, Ansong D, Asante K, Kwarteng OS, Owusu R, et al. (2009) Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4: e7302. 10.1371/journal.pone.0007302 [doi].
9. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 370: 1543-1551. S0140-6736(07)61542-6 [pii];10.1016/S0140-6736(07) 61542-6 [doi].
10. Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, et al. (2008) Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 359: 2533-2544. NEJMoa0807773 [pii];10.1056/NEJMoa0807773 [doi].
11. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, et al. (2010) Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 202: 1076-1087. 10.1086/656190 [doi].
12. Thera MA, Doumbo OK, Coulibaly D, Diemert DJ, Kone A, et al. (2004) Double blind randomized controlled Phase 1 trial to evaluate the safety and immunogenicity of WRAIR's MSP1 candidate malaria antigen (FMP1) adjuvanted in GlaxosmithKline Biologicals' AS02A vs. rabies vaccine in semi-immune adults in Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene 71: 273.
13. Pichyangkul S, Tongtawe P, Kum-Arb U, Yongvanitchit K, Gettayacamin M, et al. (2009) Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28: 452-462. S0264-410X(09)01539-4 [pii];10.1016/j.vaccine.2009.10.022 [doi].
14. Narum DL, Thomas AW (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 67: 59-68. 0166-6851(94)90096-5 [pii].
15. Escalante AA, Grebert HM, Chaiyaroj SC, Magris M, Biswas S, et al. (2001) Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project. Mol Biochem Parasitol 113: 279-287. S0166-6851(01)00229-8 [pii].
16. Cortes A, Mellombo M, Mueller I, Benet A, Reeder JC, et al. (2003) Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 71: 1416-1426. (Pubitemid 36254328)
17. Duan J, Mu J, Thera MA, Joy D, Kosakovsky Pond SL, et al. (2008) Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design. Proc Natl Acad Sci U S A 105: 7857-7862. 0802328105 [pii];10.1073/pnas.0802328105 [doi].
18. Nair M, Hinds MG, Coley AM, Hodder AN, Foley M, et al. (2002) Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J Mol Biol 322: 741-753. S0022283602008069 [pii].
19. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, et al. (2005) Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc Natl Acad Sci U S A 102: 12736-12741. 0501808102 [pii];10.1073/pnas.0501808102 [doi].
20. Dutta S, Lee SY, Batchelor AH, Lanar DE (2007) Structural basis of antigenic escape of a malaria vaccine candidate. Proc Natl Acad Sci U S A 104: 12488-12493. 0701464104 [pii];10.1073/pnas.0701464104 [doi].
21. Dutta S, Sullivan JS, Grady KK, Haynes JD, Komisar J, et al. (2009) High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 4: e8138. 10.1371/journal.-pone.0008138 [doi].
22. Takala SL, Coulibaly D, Thera MA, Batchelor AH, Cummings MP, et al. (2009) Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 1: 2ra5. 10.1126/scitranslmed.3000257 [doi].
23. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, et al. (2008) Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS ONE 3: e1465.
24. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, et al. (2010) Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS ONE 5: e9041. 10.1371/journal.pone.0009041 [doi].
25. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013. 10.1056/NEJMoa1008115 [doi].
26. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, et al. (2013) Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207: 511-519. jis709 [pii];10.1093/infdis/jis709 [doi].
27. Lyke KE, Dicko A, Kone A, Coulibaly D, Guindo A, et al. (2004) Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine 22: 3169-3174. (Pubitemid 39037221)
28. Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, et al. (2007) Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25: 4203-4212. (Pubitemid 46635946)
29. Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, et al. (2010) Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J 9: 175. 1475-2875-9-175 [pii];10.1186/1475-2875-9-175 [doi].
30. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599. msm092 [pii];10.1093/molbev/msm092 [doi].
31. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R (2003) DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 19: 2496-2497. (Pubitemid 38016658)
32. Coulibaly D, Diallo DA, Thera MA, Dicko A, Guindo AB, et al. (2002) Impact of preseason treatment on incidence of falciparum malaria and parasite density at a site for testing malaria vaccines in Bandiagara, Mali. Am J Trop Med Hyg 67: 604-610. (Pubitemid 36014916)
33. Milstien J, Cardenas V, Cheyne J, Brooks A (2010) WHO policy development processes for a new vaccine: case study of malaria vaccines. Malar J 9: 182. 1475-2875-9-182 [pii];10.1186/1475-2875-9-182 [doi].